【研究發展處訊】
數學系林惠文副教授發表最新期刊論文
Chronic obstructive pulmonary disease with short-acting inhaled pharmacotherapy increases the risk of prostate cancer: A two-stage database approach
作者:Hui-Wen Lin, Li-Fong Lin, Hung-Chou Chen, Tsan-Hon Liou, Shih-Wei Huang
PLOS ONE
卷:13 期:9 文獻號碼:e0203377
出版日期:2018年9月(SCI)
摘要:
Background
Patients with chronic obstructive pulmonary disease (COPD) are at a higher risk of many types of cancer. However, specific investigation of the risk of prostate cancer and the influence of COPD pharmacotherapy in patients with COPD is lacking. This study investigated the risk and influence of COPD pharmacotherapy on risk of prostate cancer in patients with COPD.
Methods
This retrospective cohort study used data from Taiwan's Longitudinal Health Insurance Database 2005 (LHID2005). The study cohort comprised COPD patients who received treatment between 2004 and 2008, and who were identified from the LHID2005. The control cohort comprised patients without COPD and was matched to the study cohort by age and sex. Two-stage propensity score calibration with the National Health Interview Survey 2005 was performed to obtain the missing confounders of smoking, alcohol drinking, and body mass index in the LHID. The hazard ratio (HR) and adjusted HR were estimated. Moreover, the influence of inhaled medications and other related medication on the risk of prostate cancer was analyzed by Cox proportional hazard regression.
Results
The COPD cohort comprised 12,774 patients, and the control cohort comprised 38,322 patients (1:3). The incidence of prostate cancer was 633 per 100,000 person-years in the COPD cohort and 361 per 100,000 person-years in the control cohort. The propensity score calibration-adjusted HR was 1.62 (95% CI, 1.40-1.87, p < 0.001) in the COPD cohort. Further analysis revealed that the adjusted HR for the risk of prostate cancer was 1.61 (95% CI, 1.19-2.16, p = 0.002) in patients with COPD who used short-acting muscarinic antagonists (SAMAs) and 1.89 (95% CI, 1.40-2.54, p < 0.001) in patients with COPD who used short-acting beta-agonists (SABAs). COPD patients had lower risk of prostate cancer when using statin (HR = 0.63, 95% CI, 0.45-0.89, p = 0.010) or aspirin (HR = 0.55, 95% CI, 0.350.85, p = 0.008).
Conclusion
Patients with COPD are at a higher risk of prostate cancer, particularly those using SAMAs or SABAs. This finding suggests that inflammation control may be an effective strategy for decreasing the risk of prostate cancer.
Keywords
amino-acid-based coordination polymers; structural transformations; homochiral helices; self-assembly process; L-thioproline
(研究事務組小提醒)教師如有最新發表於AHCI、SSCI、SCI、EI、TSSCI、THCI、「東吳大學外語學門獎勵名單」之期刊論文,歡迎將相關資訊e-mail至rad@scu.edu.tw,研究發展處將會公告於校園頭條,以廣交流。
【文圖/研究事務組王韋翰行政助理】
類別 | 標題 | 登刊日期 |
校園頭條 | 賀!東吳3位教授入選美國史丹佛大學(Stanford University) 發布2024「全球前2%頂尖科學家」 | 10/04/2024 |
校園頭條 | 賀!東吳2位教授入榜ScholarGPS「專業領域中全球排名前1%頂尖學者」 | 10/04/2024 |
校園頭條 | 人權與正義的守護者 唐獎法治獎得主瑪麗.羅賓遜教授蒞臨東吳 提倡性別平權 世代對話 | 10/01/2024 |
校園頭條 | 千葉商科大學參訪東吳 台日友好交流再添新頁 | 10/04/2024 |
校園頭條 | 【新生探索實驗室 : AI 協力】 2024雙城記圖書館陪你走第一哩路 | 10/04/2024 |